12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VXM01: Phase I started

Vaximm began a double-blind, placebo-controlled, dose-escalation, German Phase I trial to evaluate oral VXM01 plus standard of care...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >